Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trial
A year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary tract cancer. While the investigational drug succeeded ...
April 27, 2026 07:30 AM EDTUpdated 04:44 PM R&D Updated: Compass Therapeutics' stock plummets as it unveils more data from pivotal biliary tract cancer trial Reynald Castaneda Deputy Editor A year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that